BioSpace News Archive

It has been brought to our attention that one of our employees made harassing comments to a family who was the victim of violence.

EirGenix, Inc. announced that it has entered into a license agreement with global generic and biosimilar drug manufacturer Sandoz AG, granting an exclusive license to Sandoz for right of commercialization of EirGenix ‘s breast cancer biosimilar drug, EG12014 globally with the exception of Taiwan and mainland China.

Strong U.S. product sales of A$2.2 million for third quarter of Fiscal 2019 were double second quarter sales

Aquavit Pharmaceuticals, Inc. secured a Preliminary Injunction Order in the United States District Court for the Southern District of New York in a civil action against U-Bio Med, Inc., Global Medi Products, and Nyun Shi Eum a/k/a Nyeon-Sik Eum.

Karolinska Development AB announces that The Board of Directors has decided to delay the publication of its Annual Report for 2018.

Motif Bio plc announced the appointment of Andrew Powell, J.D. as Non-executive Director, effective immediately.

Motif Bio plc announced that its notice of its Annual General Meeting have been posted to shareholders and will shortly be available for download from the Company’s website at www.motifbio.com.

Novo Nordisk announced positive results from its ELLIPSE Phase III clinical trial of Victoza (liraglutide) in treating type 2 diabetes in children aged 10 to 17. The company presented the results at the Pediatric Endocrine Society (PES)/Pediatric Academic Societies (PAS) Annual Meeting held in Baltimore, MD, and simultaneously published in the New England Journal of Medicine.

Ireland-based Horizon Pharma reported additional statistically significant secondary data from its positive Phase III study at a conference and plans to continue to share analysis at future medical conferences.

The NDA was based on positive Phase III data that shows the once-a-month treatment is as effective as the daily standard of care.